Dissecting compounded hepatocyte injury in a model of MASLD progression from human induced pluripotent stem cells

Julian Weihs,Fatima Baldo,Alessandra Cardinali,Gehad Youssef,Katarzyna Ludwik,Harald Stachelscheid,Nils Haep,Peter Tang,Igor Sauer,Pavitra Kumar,Cornelius Engelmann,Susanna Quach,Philip Bufler,Namshik Han,Milad Rezvani

DOI: https://doi.org/10.1101/2024.10.10.617610

2024-10-11

Abstract:Metabolic dysfunction-associated steatotic liver disease (MASLD) is a complex, multifactorial condition influenced by genetic predisposition, inter-organ signaling, and immune cell infiltration. The difficulty of modeling the complex nature of the disease makes it increasingly challenging to identify treatments that intercept its progression. Here, we show the suitability of cumulative injury modeling toward steatohepatitis from hepatocyte-like cells (HLCs) generated from human induced pluripotent stem cells (iPSCs). These include insults such as free fatty acid excess, soluble extra-hepatic signaling, pro-inflammatory immune cell co-culture and genomic modifiers (PNPLA3-I148M variant). We harness this model to elucidate the molecular and functional consequences of hepatocellular injury progression and identify suitable points of therapeutic interception. Both healthy and PNPLA3-I148M iPSC-donor derived HLCs developed high-level generic steatosis response, yet the PNPLA3-I148M line was more susceptible to mitochondrial injury by the adipokine resistin and the myokine myostatin. Co-culture with peripheral blood mononuclear cells (PBMCs) compounded the previous multi-hit injury. Further, transcriptomic data revealed inflammatory HLC reprogramming and loss of genomically encoded mitochondrial metabolism along injury progression. We demonstrate a nuanced spectral metabolic injury model, mirroring clinical MASLD progression, suitable for testing stage and donor-specific disease interceptions.

Cell Biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the difficulty in modeling the complex multifactorial nature of Metabolic Dysfunction - Associated Steatotic Liver Disease (MASLD). MASLD is a disease affected by multiple factors such as genetic predisposition, inter - organ signal transduction, and immune cell infiltration. Due to its complex pathophysiological processes, existing models are difficult to fully simulate the progression of the disease, thus limiting the development of effective treatment strategies.

To overcome these challenges, researchers used Hepatocyte - like cells (HLCs) generated from human induced pluripotent stem cells (iPSCs) to construct a cumulative injury model to simulate the disease process from simple steatosis to Metabolic Dysfunction - Associated Steatohepatitis (MASH). This model includes multiple injury factors, such as excess free fatty acids, soluble extra - hepatic signals, co - culture of pro - inflammatory immune cells, and genomic modifications (e.g., PNPLA3 - I148M variant). Through this model, researchers aim to elucidate the molecular and functional consequences in the progression of hepatocyte injury and identify key points suitable for therapeutic intervention.

Specifically, this study addressed the above problems through the following steps:
1. **Cell line selection and treatment**: Use human iPSCs carrying different PNPLA3 genotypes to generate HLCs through a specific differentiation protocol.
2. **Establishment of cumulative metabolic injury model**: Gradually introduce different injury factors into HLCs, including excess free fatty acids, addition of Resistin and Myostatin, and co - culture with Peripheral Blood Mononuclear Cells (PBMCs).
3. **Multilevel analysis**: Combine multi - aspect evaluations such as lipid accumulation, mitochondrial function changes, and transcriptomics data to reveal the response characteristics of HLCs under different injury conditions.
4. **Mechanism exploration**: Through transcriptomics analysis, especially KEGG pathway enrichment analysis, explore the changes in molecular mechanisms under different injury conditions, especially inflammation reprogramming and loss of nuclear - encoded mitochondrial metabolism.

In conclusion, this study provides a new tool for testing stage - specific disease interventions by constructing a refined spectral metabolic injury model that can reflect the progression of clinical MASLD.